JPRN-jRCTb050190123
Recruiting
未知
Therapeutic angiogenesis using bone marro w-derived mononuclear cells implantation for critical limb ischemia (Therapeutic angiogenesis for critical limb ischemia) - Therapeutic angiogenesis using bone marro w-derived mononuclear cells implantation for critical limb ischemia (Therapeutic angiogenesis for critical limb ischemia)
Matoba Satoaki0 sites50 target enrollmentMarch 26, 2020
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- critical limb ischemia (arteriosclerosis obliterans, Buerger's disease, collagen disease vasculitis)
- Sponsor
- Matoba Satoaki
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •We enroll patients included all of the inclusion criteria.
- •1\) Patients who are over 20 years old and under 80 years old when obtaining written consent.
- •2\) Any gender is acceptable.
- •3\) Fontaine III\-severe severe ischemic limb (occlusive arteriosclerosis, Buerger's disease, vasculitis due to collagen disease).
- •4\) Patients who have been confirmed that there is no recovery after applying the standard treatment listed in the insurance, or who are judged to have no indication for revascularization by vascular surgeons and cardiologists, and who will be forced to have amputation in the future. (Includes patients with the possibility of small amputation.) (\*)
- •5\) Regarding the benefits / disadvantages arising from receiving a cell transplant and the benefits / disadvantages arising from not receiving a cell transplant, the patient's will and / or family's understanding and consent will be fully explained in the consent explanation document. Patients who have obtained written consent to participate in the study.
- •(\*) Standard treatment listed in insurance '' refers to drug therapy such as blood flow improving drugs and anti\-inflammatory analgesics, exercise therapy, sympathetic ganglion block, and revascularization such as percutaneous angioplasty and bypass.
Exclusion Criteria
- •1\) Even if the disease and the surgical procedure are appropriate, informed consent cannot be obtained from the patient, or emotional consideration is required for the patient's family and it is difficult to adapt.
- •2\) Life expectancy is less than one year due to other complications.
- •3\) When a malignant tumor is diagnosed.
- •4\) If you have ischemic heart disease and have not been revascularized.
- •5\) If you have severe diabetic retinopathy and have not been treated.
- •6\) If you have a serious infection.
- •7\) When severe liver dysfunction or renal dysfunction (excluding maintenance dialysis patients) exists.
- •8\) When there are severe blood disorders such as leucopenia and thrombocytopenia and severe anemia requiring blood transfusion.
- •9\) Pregnant and possibly pregnant or breastfeeding.
- •10\) Those who participated in clinical trials or clinical trials for pharmaceuticals or medical devices at the same time as this trial or within 30 days before enrollment in this trial.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Suspended
Not Applicable
Therapeutic angiogenesis using bone marrow-derived mononuclear cells implantation for critical limb ischemiawith Buerger's diseasecritical limb ischemia caused by Buerger's diseasecritical limb ischemia, Buerger'a diseaseJPRN-jRCTb050190082Matoba Satoaki25
Not yet recruiting
Not Applicable
Therapeutic angiogenesis using autologous bone marrow mononuclear cells implantation for Buerger diseaseCLI(Critical limb ischemia) (Buerger disease)JPRN-UMIN000027383Kyoto Prefectural University School of Medicine25
Completed
Not Applicable
Therapeutic Angiogenesis using Autologous Bone-Marrow Mononuclear Cells ImplantatioCLI(Critical limb ischemia) (ASO, Buerger disease, Collagen disease)JPRN-UMIN000023282Kyoto Prefectural University School of Medicine120
Completed
Phase 1
A clinical trial to evaluate the effect of bone marrow derived stem cell in diseases Limb IschemiaHealth Condition 1: null- Limb IschemiaCTRI/2010/091/000565Department of Biotechnology New Delhi80
Completed
Phase 1
Vascular regeneration using autologous mesenchymal stem cells for peripheral arterial diseasePeripheral Arterial Disease (Fontaine stages three and four)JPRN-UMIN000009943Rogenkai Welfare Group5